Quoted message said:
Al. Lohse said:It is an elephant; Your quotes are mice. Agreed?
A.L.
Your reply (in essence "my citations are better than your citations"😉 proves my point. I'm having
deja vu all over again.
My citation also gives mention of process, information about the players, and funding arrangements.
So, "in essence," you are correct.
Quoted message said:
Let me ask you a question:
Do statins provide an overall health benefit in secondary prevention?
(You can just answer yes or no).
Yes, .... most probably, yes.
I cannot give an absolute opinion on that matter. UBC TI in letter #49
ti.ubc.ca49.pdfOpen ↗
suggests there be a benefit. In order for them to reach that conclusion they had to take industry
funded research as fact. I do not. It needs to be audited and/or repeated. (Skeptics suggest any
benefit is independent of cholesterol profile alteration.) It is a pity ALLHAT-LLT, a large,
publicly funded trial, found no effect. A discovered effect there would have been definitive. A
discovered non-effect is ignored.
"Conclusions Pravastatin did not reduce either all-cause mortality or CHD significantly when
compared with usual care in older participants with well-controlled hypertension and moderately
elevated LDL-C. ...." JAMA. 2002;288:2998-3007 www.jama.com
When I see mankind in self-interest-mode, he is liable to distort reality. While he can be at his
best in self-interest-mode, he is also capable of being at his worst.
Personally, I had been asked to alter some data in a research project with trivial economical effect
on anyone. It is not difficult to do. The request may have been a test on me to see if I *would* do
it. I refused. Also, unlike that professor who asked me, I would have published negative results;
Results that did not measure up to the theory. There is information in negative results, sometimes
valuable information.
I know, however, altering data can be done, and in a field related to mechanical engineering where
economics and self interest were at play a graduate engineer had confided in me that he altered
data. (Public safety was not at risk.) It happens.
The publication of 4S in which the authors confided that the sponsor had an insider working with
them should sound an alarm to all. If s/he was not massaging data, why was he (or she) there?
To conclude, however, the benefits of statin treatment in secondary prevention are not great. (Like,
where is the elephant?) If they were great, there would be no need for discussion and clinical
trials would be positive and entirely supportive of one another.
If I had blocked coronary arteries, bypass, stents, or angioplasty, I would take statins if I could
tolerate them. They just might give one a slight survival edge. But, if I found myself sliding into
the abyss as Mr. Hope, Sharon's husband, I would forget about that slight edge and choose quality of
life over quantity of life. Everyone should be thankful to, certainly not critical of, Sharon for
telling us how things can go so terribly wrong!
My purpose in this matter is to minimize drug damage not only to myself, but also to others. Laying
out the facts and openly discussing them is a step in that direction. Four years ago I would have
thought that drugs damaging patients would be nearly impossible, excedingly rare; Today I find it to
be all too common, too irresponsible.
If it is agreed that ti.ubc.ca48.pdfOpen ↗ is an elephant, then the no fewer than three
*unchallenged* books written on the subject are whales. Sound bites like, "Dr. Alphonso Phritz says
the implications of the results of this study are enormous." simply do not (and should not) cut it.
Oft repetition does not a truth make.
Regards and thanks for your civility,
A.L.